These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 17172884

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure.
    Angus DC, Linde-Zwirble WT, Tam SW, Ghali JK, Sabolinski ML, Villagra VG, Winkelmayer WC, Worcel M, African-American Heart Failure Trial (A-HeFT) Investigators.
    Circulation; 2005 Dec 13; 112(24):3745-53. PubMed ID: 16344404
    [Abstract] [Full Text] [Related]

  • 7. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology.
    Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A, Ofili E, Ferdinand K, Loscalzo J, Worcel M, A-HeFT Investigators.
    J Card Fail; 2002 Jun 13; 8(3):128-35. PubMed ID: 12140804
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
    Tam SW, Sabolinski ML, Worcel M, Packer M, Cohn JN.
    Clin Pharmacokinet; 2007 Jun 13; 46(10):885-95. PubMed ID: 17854237
    [Abstract] [Full Text] [Related]

  • 10. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
    Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN, African-American Heart Failure Trial Investigators.
    N Engl J Med; 2004 Nov 11; 351(20):2049-57. PubMed ID: 15533851
    [Abstract] [Full Text] [Related]

  • 11. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
    Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, Adams K, Olukotun AY, Ofili E, Tam SW, Sabolinski ML, Worcel M, Cohn JN, African-American Heart Failure Trial Investigators.
    Circulation; 2007 Apr 03; 115(13):1747-53. PubMed ID: 17372175
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety.
    Ferdinand KC.
    Expert Rev Cardiovasc Ther; 2005 Nov 03; 3(6):993-1001. PubMed ID: 16292990
    [Abstract] [Full Text] [Related]

  • 15. Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction.
    Golwala HB, Thadani U, Liang L, Stavrakis S, Butler J, Yancy CW, Bhatt DL, Hernandez AF, Fonarow GC.
    J Am Heart Assoc; 2013 Aug 21; 2(4):e000214. PubMed ID: 23966379
    [Abstract] [Full Text] [Related]

  • 16. BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective.
    Temple R, Stockbridge NL.
    Ann Intern Med; 2007 Jan 02; 146(1):57-62. PubMed ID: 17200223
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.